CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Часто задаваемые вопросы
В каком секторе работает CytoMed Therapeutics Limited Ordinary Shares (GDTC)?
CytoMed Therapeutics Limited Ordinary Shares относится к сектору Здравоохранение.
Какова текущая цена акций CytoMed Therapeutics Limited Ordinary Shares (GDTC)?
По последним данным, цена акций CytoMed Therapeutics Limited Ordinary Shares составляет 0,88 $, предыдущее закрытие — 0,89 $. За последнюю торговую сессию акции CytoMed Therapeutics Limited Ordinary Shares снизились на -0,01 $, что соответствует падению на -0,96%.
Выплачивает ли CytoMed Therapeutics Limited Ordinary Shares (GDTC) дивиденды?
Нет, CytoMed Therapeutics Limited Ordinary Shares не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у CytoMed Therapeutics Limited Ordinary Shares (GDTC)?
У компании CytoMed Therapeutics Limited Ordinary Shares бета 0.024, что указывает на более низкую волатильность по сравнению с рынком в целом.
